CMPX
Compass Therapeutics, Inc.
There isn't enough reported data to score CMPX yet.
CMPX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CMPX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
CMPX PE Valuation
CMPX has no meaningful PE right now: it lost money over the past year.
CMPX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CMPX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
CMPX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.48 | -$0.03 |
| Q2 2026 | -$0.41 | +$0.04 |
| Q1 2026 | -$0.42 | -$0.01 |
| Q4 2025 | -$0.44 | -$0.07 |
| Q3 2025 | -$0.45 | -$0.08 |
| Q2 2025 | -$0.45 | -$0.08 |
| Q1 2025 | -$0.41 | -$0.05 |
| Q4 2024 | -$0.37 | -$0.03 |
CMPX is still losing money, but far less than before: $0.48 per share over the past year, against $1.31 at its worst in late 2021.
CMPX Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2024 | -1770% | N/A |
CMPX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$16.4M | -$5.6M |
| Q2 2026 | -$14.9M | -$3.1M |
| Q1 2026 | -$17.4M | -$4.1M |
| Q4 2025 | -$13.3M | -$4.1M |
| Q3 2025 | -$10.9M | +$239K |
| Q1 2025 | -$13.2M | +$662K |
| Q4 2024 | -$9.2M | +$3.2M |
| Q3 2024 | -$11.1M | -$5.2M |
CMPX has burned cash in almost every quarter: −$62M over the past year, against −$45M the year before.
CMPX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +11% | +18M shares |
| 3 years | +47% | +59.4M shares |
| 5 years | +260% | +135M shares |
| Available history | +3636% | +182M shares |
CMPX has 187M diluted shares, up 11% from a year ago.
CMPX Net Leverage
CMPX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CMPX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.7 | Oversold |
| Stochastic | 5.2 | Oversold |
CMPX's weekly RSI is 29 (oversold) and its Stochastic is 5 (oversold).
CMPX PE vs Healthcare Sector
CMPX has no meaningful PE right now: it lost money over the past year.
CMPX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.87 | 5.7% below |
| 20 week MA | $1.65 | 50% below |
| 50 week MA | $3.36 | 76% below |
| 100 week MA | $3.12 | 74% below |
| 200 week MA | $2.62 | 69% below |
CMPX is in a downtrend: it's below all five of its weekly moving averages, and 69% below its 200-week average.
CMPX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $8.50 | $3.05 | -64% |
| 2022 | $3.05 | $5.41 | +77% |
| 2023 | $5.41 | $1.56 | -71% |
| 2024 | $1.56 | $1.46 | -6.4% |
| 2025 | $1.46 | $5.17 | +254% |
| 2026 YTD | $5.17 | $0.82 | -84% |
CMPX's yearly returns have swung widely, from +254% in 2025 to −71% in 2023. It's down 84% so far in 2026.